Decentralized Trial Technology Insights

  1. Boehringer Ingelheim Implements One Medicine Technology Platform 12/8/2022

    For years, Boehringer Ingelheim operated with a system comprised of best-of-breed solutions from different vendor companies. After carefully evaluating the technology environment, the company decided to move from best-of-breed solutions to an end-to-end product development platform.

  2. What Astellas Has Learned About Decentralized Trials 11/28/2022

    When the COVID pandemic hit in the spring of 2020, many companies were unprepared for the changes that were about to impact their studies. Astellas is one company that was better prepared than most. The company had initiated a formalized, internal project on decentralized clinical trial (DCT) technologies and their use in clinical trials about nine months prior to the pandemic.

  3. Key Learnings To Optimize Clinical Trials During COVID-19 11/4/2022

    Designing and conducting trials during the COVID-19 global pandemic forced clinical teams to be creative, to explore the use of technology, and to design a trial that meets the participants where they are — without compromising outcomes. 

  4. What Your Sites Love And Hate About DCTs 10/25/2022

    For years, sponsor companies have had access to new and emerging technologies that would ease the participation burden of patients in clinical trials. While these emerging technologies helped sponsor companies keep their trials on track, they have also been a burden for the clinical sites having to deal with the changes required to keep up with them. Do you know where your sites stand on the adoption of hybrid trials and DCTs?

  5. Will DCTs Become The Norm? 10/5/2022

    Decentralized clinical trials (DCTs) have been an option for more than a decade, though the pandemic has been the catalyst for change. There is no doubt that DCTs and digitalization are starting to transform clinical research, but will they become the norm?

  6. Using RWE In Clinical Trials: Challenges & Opportunities 9/19/2022

    What are real-world data (RWD) and real-world evidence (RWE), and how can we overcome the challenges of integrating them into clinical trials to produce better outcomes?

  7. Walgreens Is Ready To Re-Envision Recruitment, DCTs, And RWE 9/12/2022

    Since becoming CEO of Walgreens Boots Alliance (WBA) in March 2021, Rosalind Brewer has been focused on healthcare and what the company could do to help its patients. WBA refers to the integrated healthcare, pharmacy, and retail store that currently serves millions of customers and patients every day. This past June, the company launched its clinical trial business. 

  8. Digital Solutions, Technology, And Patient Care Top Life Science Trends 9/6/2022

    Technology company Within3 has produced a paper on the six top trends that are going to impact the pharmaceutical space. It’s no surprise that technology solutions were one of the trends making the list, but also included were factors such as patients, cyber threats, and a growing global marketplace.

  9. Pharma Companies Are Tapping Digital Health For Improved Patient Outcomes 8/11/2022

    Smarter diagnostic tools and a growing role for remote care will be of huge importance in the new paradigm. The pharma industry, which is already growing its role in delivering hybrid solutions combining therapies with diagnostic and smart solutions and devices, could play a significant role here.

  10. Tufts Finds Substantial Net Benefits To Using Decentralized Trials 7/28/2022

    For years, vendors have touted decentralized clinical trials (DCTs) as a solution to both the time and cost challenges. DCTs also promise to make trials more patient centric. Unfortunately, a demonstration of the actual benefits of DCTs, along with a quantifiable dollar amount, have been difficult to produce. Until now.